Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Special Report—Run-Up to the 2026 Midterms

    As November 3 midterm elections draw closer, investors are increasingly starting to think about what the potential outcomes might mean for financial market performance.

    Read more

  • Brakebush Brothers Has Agreed to be Acquired by Hormel Foods

    William Blair acted as the exclusive financial advisor to Brakebush Brothers, Inc., in connection with its pending sale to Hormel Foods Corporation (NYSE: HRL) for $1.055 billion.

    Read more

  • Rising Prices Are Testing the Limits of Rideshare Demand

    Rideshare demand remains resilient, but growing price fatigue could challenge future growth.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures